In BRCA mutation carriers breast conserving surgery may not be the best choice
- 80 Downloads
To the Editor,
We read with great interest the article by Cao and coworkers entitled Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China published online on March 2019 . Authors retrospectively examined whether mutational status influences the rate of ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) in Chinese women. A cohort of 1947 patients who underwent BCS were selected with 31 BRCA1 and 72 BRCA2 mutation carriers identified among them. At a median follow-up of 80 months, no significant difference resulted in IBTR between carriers and non-carriers (3.9% vs. 2.0%, p = 0.16). Notably, all IBTR among carriers turned out to be new primary tumors, which were significantly more frequent in carriers compared to non-carriers (3.9% vs. 0.6%, p = 0.01). A significant difference in contralateral breast cancers was also found between carriers and non-carriers...
Compliance with ethical standards
Conflict of interest
F. Sardanelli has received grants from and is member of speakers’ bureau/advisory board for Bayer, Bracco, and General Electric companies. R. M. Trimboli and S. Schiaffino declare that they have no conflict of interest.
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Cao W, Xie Y, He Y, Li J, Wang T, Fan Z, Fan T, Ouyang T (2019) Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China. Breast Cancer Res Treat 175:749–754. https://doi.org/10.1007/s10549-019-05199-8 CrossRefPubMedGoogle Scholar